Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Objective: The aim was to study the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cells in adults with B-cell lymphoma. Methods: From October 2015 to October 2021, we treated five patients with B-cell lymphoma, comprising two with mantle cell lymphoma, one case of Burkitt lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wenyujing, Chen, Weihong, Wan, Xiaochun, Luo, Changru, Du, Xin, Li, Xiaoqing, Chen, Qian, Gao, Ruiwen, Zhang, Xiaohan, Xie, Mei, Wang, Mingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811184/
https://www.ncbi.nlm.nih.gov/pubmed/35126471
http://dx.doi.org/10.3389/fgene.2021.815679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811184/
https://www.ncbi.nlm.nih.gov/pubmed/35126471
http://dx.doi.org/10.3389/fgene.2021.815679

Ejemplares similares